PriceTargets.com logo

Keros Therapeutics - KROS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $86.00
  • Forecasted Upside: 45.89%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$58.95 As of 04/18/2024 01:00 AM ET
▼ -0.32 (-0.54%)

This chart shows the closing price for KROS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Keros Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KROS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KROS

Analyst Price Target is $86.00
▲ +45.89% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Keros Therapeutics in the last 3 months. The average price target is $86.00, with a high forecast of $105.00 and a low forecast of $60.00. The average price target represents a 45.89% upside from the last price of $58.95.

This chart shows the closing price for KROS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in Keros Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/27/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$105.00Low
3/13/2024Truist FinancialReiterated RatingBuy ➝ Buy$100.00Low
3/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00Low
2/29/2024WedbushReiterated RatingOutperform$86.00Low
2/21/2024William BlairReiterated RatingOutperformLow
1/3/2024WedbushReiterated RatingOutperform$86.00Low
12/8/2023Wells Fargo & CompanyInitiated CoverageOverweight$60.00Low
11/13/2023WedbushReiterated RatingOutperform ➝ Outperform$86.00Low
8/31/2023WedbushReiterated RatingOutperform ➝ Outperform$86.00Low
8/8/2023WedbushReiterated RatingOutperform ➝ Outperform$86.00Low
8/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$100.00Low
7/31/2023WedbushInitiated CoverageOutperform$86.00Low
7/26/2023Bank of AmericaInitiated CoverageBuy$65.00Low
5/5/2023Piper SandlerLower Target$120.00 ➝ $110.00Low
3/6/2023HC WainwrightReiterated RatingBuy$100.00Low
2/14/2023CowenInitiated CoverageOutperformLow
2/14/2023CowenInitiated CoverageOutperformLow
12/13/2022BTIG ResearchBoost TargetBuy$95.00 ➝ $105.00Low
10/18/2022Truist FinancialInitiated CoverageBuy$100.00N/A
9/13/2022BTIG ResearchBoost Target$80.00 ➝ $95.00Low
7/26/2022BTIG ResearchInitiated CoverageBuy$80.00Low
6/10/2022HC WainwrightReiterated RatingBuy$100.00High
5/18/2022Piper SandlerBoost TargetNA$90.00 ➝ $120.00High
3/10/2022HC WainwrightReiterated RatingBuy$100.00High
8/9/2021HC WainwrightReiterated RatingBuy$100.00Medium
8/6/2021Piper SandlerLower TargetOverweight$95.00 ➝ $90.00Low
6/27/2021SVB LeerinkReiterated RatingBuyLow
6/23/2021Jefferies Financial GroupReiterated RatingBuy$70.00High
12/8/2020HC WainwrightBoost TargetBuy$50.00 ➝ $100.00High
12/8/2020SVB LeerinkBoost TargetOutperform$42.00 ➝ $80.00High
12/8/2020Piper SandlerBoost TargetOverweight$75.00 ➝ $95.00High
11/18/2020Piper SandlerBoost TargetOverweight$55.00 ➝ $75.00Low
9/13/2020Piper SandlerBoost TargetOverweight$45.00 ➝ $55.00Medium
5/27/2020Piper SandlerBoost TargetOverweight$35.00 ➝ $45.00High
5/4/2020HC WainwrightInitiated CoverageBuy$50.00Medium
5/4/2020SVB LeerinkInitiated CoverageOutperform$42.00Medium
5/4/2020Jefferies Financial GroupInitiated CoverageBuy$37.00Medium
5/3/2020Piper SandlerInitiated CoverageOverweight$35.00Medium
(Data available from 4/19/2019 forward)

News Sentiment Rating

1.23 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2023
  • 7 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 12 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 14 very positive mentions
  • 21 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 9 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 9 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Keros Therapeutics logo
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: $58.95
Low: $58.15
High: $61.33

50 Day Range

MA: $63.72
Low: $53.59
High: $70.48

52 Week Range

Now: $58.95
Low: $27.02
High: $73.00

Volume

296,468 shs

Average Volume

265,797 shs

Market Capitalization

$2.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Frequently Asked Questions

What sell-side analysts currently cover shares of Keros Therapeutics?

The following Wall Street analysts have issued stock ratings on Keros Therapeutics in the last twelve months: Bank of America Co., HC Wainwright, Piper Sandler, Truist Financial Co., Wedbush, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for KROS.

What is the current price target for Keros Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Keros Therapeutics in the last year. Their average twelve-month price target is $86.00, suggesting a possible upside of 45.9%. Piper Sandler has the highest price target set, predicting KROS will reach $105.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $60.00 for Keros Therapeutics in the next year.
View the latest price targets for KROS.

What is the current consensus analyst rating for Keros Therapeutics?

Keros Therapeutics currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KROS will outperform the market and that investors should add to their positions of Keros Therapeutics.
View the latest ratings for KROS.

What other companies compete with Keros Therapeutics?

Other companies that are similar to Keros Therapeutics include Dyne Therapeutics, Maravai LifeSciences, TG Therapeutics, Rocket Pharmaceuticals and Amphastar Pharmaceuticals. Learn More about companies similar to Keros Therapeutics.

How do I contact Keros Therapeutics' investor relations team?

Keros Therapeutics' physical mailing address is 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421. The company's listed phone number is 617-314-6297 and its investor relations email address is [email protected]. The official website for Keros Therapeutics is www.kerostx.com. Learn More about contacing Keros Therapeutics investor relations.